Fifteen patients with conjunctival melanoma developed recurrent disease and eleven patients with conjunctival melanoma developed metastatic disease, with most of the cases with metastatic disease harboring either a TERT promoter mutation or ATRX loss. Here, ATRX is linked to malignant conjunctival melanoma.